Clinigen (CLIN) is acquiring the US rights to cancer drug Proleukin from Swiss pharma giant Novartis (NOVN) for $210m (£163m) in cash, with $120m due upfront. Clinigen has owned the rights to Proleukin outside of the US since July 2018, but this latest transaction now makes it the exclusive global owner of the licensed version of this drug.
IC TIP:
Buy
at
862p
The treatment is active in roughly 80 clinical studies in the US across “multiple” disease areas, while Clinigen bosses say the drug could become “an integral part” of future cancer combination therapies. For the year to 30 June 2018, Proleukin logged sales of $60m in the US, while the gross profit margin should match other speciality medicines within Clinigen’scommercial medicines division.
